Immunotoxicity of Pharmaceuticals: Current Knowledge, Testing Strategies, Risk Evaluation & Consequences for Human Health-Reference-Cited by-同舟云学术

Immunotoxicity of Pharmaceuticals: Current Knowledge, Testing Strategies, Risk Evaluation & Consequences for Human Health

Published:1997-10 Issue:4 Volume:31 Page:1301-1305
ISSN:0092-8615
Container-title:Drug Information Journal
language:en
Short-container-title:Drug Information J

Author:

van der Laan Jan Willem,van Loveren Henk,Vos Jeff G.,Dean Jack H.,Hastings Kenneth L.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Public Health, Environmental and Occupational Health,Drug Guides,Pharmacology (nursing)

Link

http://link.springer.com/content/pdf/10.1177/009286159703100429.pdf

Reference4 articles.

1. DIA Workshop “Immunotoxicity of pharmaceuticals: Current knowledge, testing strategies, risk evaluation & consequences for human health,” October 2–4, 1997, Montreux, Switzerland.

2. De Waal EJ, Van Loveren H, Vos JG. Practice of tiered testing for immunosuppressin in rodents. Drug Inf J. 1997,31(4).

3. Albers R. Suitability of the PLN assay as a predictive immunotoxicological test. Drug InfJ. 1997;31(4).

4. Talal N, Dang H. Drug-induced autoimmunity and autoimmune disease. Drug InfJ. 1997;31(4).

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regulatory Guidance: ICH, EMA, FDA;Drug Discovery and Evaluation: Methods in Clinical Pharmacology;2020

2. Immunotoxicology: A Brief History;Methods in Molecular Biology;2018

3. Regulatory Guidance: ICH, EMA, FDA;Drug Discovery and Evaluation: Methods in Clinical Pharmacology;2018

4. A proteomic approach for the identification of immunotoxic properties of Tulipalin A;PROTEOMICS;2016-11-15

5. ICH S8: History and Perspectives;Global Approach in Safety Testing;2013